Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC2 | Q92769 | 7/20 | 0.81 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.69 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15685265 | 0.89 | HDAC2 (1.00) | HDAC2HDAC1HDAC3 | |
| SCHEMBL15654502 | 0.83 | HDAC2 (0.74) | HDAC2HDAC1HDAC3 | |
| SCHEMBL27891708 | 0.83 | KDM4E (0.64) | HDAC2HDAC1HDAC3KDM4EHSD17B10 | |
| Bromide SCHEMBL15653791 | 0.82 | HDAC2 (0.72) | HDAC2HDAC1HDAC3 | |
| SCHEMBL15685116 | 0.80 | HDAC2 (1.00) | HDAC2HDAC1HDAC3 | |
| SCHEMBL2135459 | 0.79 | HDAC1 (0.65) | HDAC2HDAC1HDAC3 | |
| SCHEMBL15685085 | 0.79 | HDAC2 (0.82) | HDAC2HDAC1HDAC3 | |
| SCHEMBL15685084 | 0.79 | HDAC2 (1.00) | HDAC2HDAC1HDAC3 | |
| SCHEMBL15933368 | 0.79 | HDAC2 (1.00) | HDAC2HDAC1HDAC3 | |
| SCHEMBL15685083 | 0.79 | HDAC2 (0.80) | HDAC2HDAC1HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150374646-A1 | TREATMENT OF CANCER AND OTHER CONDITIONS USING A TRANSCRIPTION FACTOR MODULATOR | C & C BIOPHARMA LLC (US) | 2015-12-31 | — | — | US | disclosed |
| US-20140256776-A1 | TREATMENT OF CANCER AND OTHER CONDITIONS USING A TRANSCRIPTION FACTOR MODULATOR | C&C BIOPHARMA, LLC | 2014-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256776-A1 | TREATMENT OF CANCER AND OTHER CONDITIONS USING A TRANSCRIPTION FACTOR MODULATOR | RELA, NCOA1, NCOA2 | HDAC2 290/4885HDAC1 163/4885HDAC3 287/4885 |
| US-20150374646-A1 | TREATMENT OF CANCER AND OTHER CONDITIONS USING A TRANSCRIPTION FACTOR MODULATOR | RELA, NCOA1, NCOA2 | HDAC2 290/4885HDAC1 163/4885HDAC3 287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.